Report

NATCO Pharma announces US launch of generic carboplatin injection

The Economic Times reports NATCO Pharma USA's Paraplatin generic launch involves Chennai-based manufacturing collaborator Teyro Labs.

1 Source, 21d ago, first seen 21d ago

TLDR

NATCO Pharma announced the US launch of Carboplatin Injection, a generic version of Paraplatin, through NATCO Pharma USA, The Economic Times reports. Chennai-based Teyro Labs is its manufacturing collaborator. The company says the launch aims to address a critical shortage of a drug used to treat advanced ovarian carcinoma. The report does not quantify new supply or say whether the shortage has eased.

Today's Rank

—

Not ranked yet

Combined views

1 Source, first seen 21d ago

NATCO Pharma announced the US launch of Carboplatin Injection, a generic version of Paraplatin, through its subsidiary NATCO Pharma USA, The Economic Times reported Oct. 19. The report said the subsidiary would launch the product in a manufacturing collaboration with Chennai-based Teyro Labs Pvt Ltd.

Featured Source

A company release described by The Economic Times says carboplatin injection is used to treat advanced ovarian carcinoma. Its uses include first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy, the report said.

NATCO said the launch aims to address what it called a critical shortage of the drug in the United States, according to the report. The Economic Times did not quantify how much new supply the launch would bring or report that the shortage had eased.

NATCO Pharma announces US launch of generic carboplatin injection

TLDR

Combined views

Combined views

1 Source

Comments

1 Source

1 Source

1 Source

1 Source

1 Source

1 Source

1 Source

Comments